Tiny study hopes bulevirtide eases liver pressure in hepatitis d
NCT ID NCT04863703
First seen Nov 01, 2025 · Last updated Jun 20, 2026 · Updated 35 times
Summary
This observational study follows 11 people with chronic hepatitis B and D coinfection and liver cirrhosis who are already taking Bulevirtide. Researchers want to see if the drug reduces portal hypertension (high blood pressure in the liver), which is a major cause of complications. They will measure liver pressure and quality of life over time.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LIVER CIRRHOSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hannover Medical School
Hanover, Lower Saxony, 30625, Germany
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Bulevirtide
What this could lead to
If successful, this could show that antiviral treatment helps reduce liver pressure and improve outcomes for people with hepatitis D and cirrhosis.
What could go wrong
This is a very small observational study (11 people) with no control group, so results may not be widely applicable. The treatment is already approved, but its effect on portal hypertension is not yet proven.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.